This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Best And Worst Performing Biotech Stocks In the Second Quarter

IBB Chart IBB data by YCharts

BOSTON ( TheStreet) -- Biotech investors will be happy with the chart above as the sector's benchmark index continues to outperform the broader market in the second quarter.

The iShares Nasdaq Biotechnology Index Fund closed the June quarter up 8.9 percent compared to a 2.8 percent rise in the S&P 500. The biotech index has been on a consistent downtrend since the middle of May, which bears watching.

Here are the five top-performing bio-pharma stocks in the second quarter:

No. 5: Vanda Pharmaceuticals (VNDA - Get Report) VNDA Chart VNDA data by YCharts

Vanda is developing tasimelteon as a treatment for a rare sleep disorder which affects blind people. Vanda shares fell in June after questions were raised about the company's clinical development of tasimelteon, raising the risk that the drug would be rejected by FDA.

No. 4: Stemline Therapeutics (STML - Get Report) STML Chart STML data by YCharts

Stemline is developing drugs which target cancer stem cells. The company's shares rose following the presentation of clinical data at the American Society of Clinical Oncology annual meeting in early June.

No. 3: Immunomedics (IMMU - Get Report) IMMU Chart IMMU data by YCharts

Immunomedics will be presenting results from a phase I study of the experimental radio-labeled monoclonal antibody Clivatuzumab tetraxetan at a medical meeting, July 3-6.

No. 2: Acadia Pharmaceuticals (ACAD - Get Report) ACAD Chart ACAD data by YCharts

Acadia continues to be one of the strongest-performing stocks in the biotech sector this year, supported by investor excitement for the company's Parkinson's psychosis drug pimavanserin.

No. 1: Clovis Oncology (ACAD - Get Report) CLVS Chart CLVS data by YCharts

Clovis is not only the best-performing stock in the second quarter, but it's also No. 1 for all of 2013 so far. Why? The experimental lung cancer drug CO-1686.

Not all bio-pharma stocks enjoyed success in the second quarter. The worst-performing stocks for the June quarter were:

No. 5: Cardium Therapeutics (CXM) -56%
No. 4: Aveo Pharmaceuticals (AVEO) -66%
No. 3: Infinity Pharmaceuticals (INFI - Get Report) -67%
No. 2: Echo Therapeutics (ECTE) -68%

No. 1: GenVec (GNVC): -75%

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACAD $27.53 0.00%
CLVS $13.19 0.00%
IMMU $3.74 0.00%
INFI $5.44 0.00%
STML $5.10 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs